ID   NAAA_HUMAN              Reviewed;         359 AA.
AC   Q02083; Q5KTF2; Q96EY2; Q9BRA8;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 149.
DE   RecName: Full=N-acylethanolamine-hydrolyzing acid amidase;
DE            EC=3.5.1.-;
DE   AltName: Full=Acid ceramidase-like protein;
DE   AltName: Full=N-acylsphingosine amidohydrolase-like;
DE            Short=ASAH-like protein;
DE   Contains:
DE     RecName: Full=N-acylethanolamine-hydrolyzing acid amidase subunit alpha;
DE   Contains:
DE     RecName: Full=N-acylethanolamine-hydrolyzing acid amidase subunit beta;
DE   Flags: Precursor;
GN   Name=NAAA; Synonyms=ASAHL, PLT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=10610717; DOI=10.1006/geno.1999.5953;
RA   Hong S.-B., Li C.-M., Rhee H.-J., Park J.-H., He X., Levy B.,
RA   Yoo O.J., Schuchman E.H.;
RT   "Molecular cloning and characterization of a human cDNA and gene
RT   encoding a novel acid ceramidase-like protein.";
RL   Genomics 62:232-241(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ENZYME REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND
RP   GLYCOSYLATION.
RX   PubMed=15655246; DOI=10.1074/jbc.M413473200;
RA   Tsuboi K., Sun Y.-X., Okamoto Y., Araki N., Tonai T., Ueda N.;
RT   "Molecular characterization of N-acylethanolamine-hydrolyzing acid
RT   amidase, a novel member of the choloylglycine hydrolase family with
RT   structural and functional similarity to acid ceramidase.";
RL   J. Biol. Chem. 280:11082-11092(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 81-359 (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=1446826; DOI=10.1016/0378-1119(92)90133-A;
RA   Goodchild N.L., Wilkinson D.A., Mager D.L.;
RT   "A human endogenous long terminal repeat provides a polyadenylation
RT   signal to a novel, alternatively spliced transcript in normal
RT   placenta.";
RL   Gene 121:287-294(1992).
RN   [5]
RP   PROTEIN SEQUENCE OF N-TERMINUS, CATALYTIC ACTIVITY, PROTEOLYTIC
RP   CLEAVAGE, GLYCOSYLATION AT ASN-37; ASN-107; ASN-309 AND ASN-333,
RP   ACTIVE SITE, AND SUBUNIT.
RX   PubMed=22040171; DOI=10.1021/pr200735a;
RA   West J.M., Zvonok N., Whitten K.M., Wood J.T., Makriyannis A.;
RT   "Mass spectrometric characterization of human N-acylethanolamine-
RT   hydrolyzing acid amidase.";
RL   J. Proteome Res. 11:972-981(2012).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-37.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
CC   -!- FUNCTION: Degrades bioactive fatty acid amides to their
CC       corresponding acids, with the following preference: N-
CC       palmitoylethanolamine > N-myristoylethanolamine > N-
CC       lauroylethanolamine = N-stearoylethanolamine > N-
CC       arachidonoylethanolamine > N-oleoylethanolamine. Also exhibits
CC       weak hydrolytic activity against the ceramides N-
CC       lauroylsphingosine and N-palmitoylsphingosine.
CC       {ECO:0000269|PubMed:15655246}.
CC   -!- ENZYME REGULATION: Stimulated by DTT and Nonidet P-40.
CC       {ECO:0000269|PubMed:15655246}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=97 uM for N-palmitoylethanolamine
CC         {ECO:0000269|PubMed:15655246};
CC       pH dependence:
CC         Optimum pH is 4.5 with N-palmitoylethanolamine as substrate.
CC         {ECO:0000269|PubMed:15655246};
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit, non-
CC       covalently linked. {ECO:0000269|PubMed:22040171}.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000305|PubMed:10610717,
CC       ECO:0000305|PubMed:15655246}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q02083-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q02083-2; Sequence=VSP_000330;
CC       Name=3;
CC         IsoId=Q02083-3; Sequence=VSP_000328, VSP_000329;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest
CC       levels in liver and kidney, followed by pancreas.
CC       {ECO:0000269|PubMed:10610717}.
CC   -!- PTM: N-glycosylated. Tunicamycin treatment causes a reduction in
CC       specific activity against N-palmitoylethanolamine.
CC       {ECO:0000269|PubMed:15655246, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:22040171}.
CC   -!- PTM: Autoproteolytic cleavage in the acidic lumen of the lysosome
CC       activates the enzyme. {ECO:0000269|PubMed:22040171}.
CC   -!- SIMILARITY: Belongs to the acid ceramidase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB161353; BAD88528.1; -; mRNA.
DR   EMBL; BC006388; AAH06388.2; -; mRNA.
DR   EMBL; BC011854; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M92449; AAA60119.1; -; mRNA.
DR   CCDS; CCDS43239.1; -. [Q02083-1]
DR   RefSeq; NP_001035861.1; NM_001042402.1. [Q02083-2]
DR   RefSeq; NP_055250.2; NM_014435.3. [Q02083-1]
DR   RefSeq; XP_005262977.1; XM_005262920.3. [Q02083-1]
DR   RefSeq; XP_005262982.1; XM_005262925.3. [Q02083-2]
DR   RefSeq; XP_016863517.1; XM_017008028.1. [Q02083-1]
DR   UniGene; Hs.437365; -.
DR   ProteinModelPortal; Q02083; -.
DR   BioGrid; 118042; 54.
DR   STRING; 9606.ENSP00000286733; -.
DR   BindingDB; Q02083; -.
DR   ChEMBL; CHEMBL4349; -.
DR   GuidetoPHARMACOLOGY; 1402; -.
DR   SwissLipids; SLP:000001125; -.
DR   MEROPS; C89.002; -.
DR   BioMuta; NAAA; -.
DR   DMDM; 116241258; -.
DR   EPD; Q02083; -.
DR   MaxQB; Q02083; -.
DR   PaxDb; Q02083; -.
DR   PeptideAtlas; Q02083; -.
DR   PRIDE; Q02083; -.
DR   Ensembl; ENST00000286733; ENSP00000286733; ENSG00000138744. [Q02083-1]
DR   Ensembl; ENST00000507956; ENSP00000427641; ENSG00000138744. [Q02083-2]
DR   GeneID; 27163; -.
DR   KEGG; hsa:27163; -.
DR   UCSC; uc003hjb.4; human. [Q02083-1]
DR   CTD; 27163; -.
DR   DisGeNET; 27163; -.
DR   GeneCards; NAAA; -.
DR   HGNC; HGNC:736; NAAA.
DR   HPA; CAB026135; -.
DR   MIM; 607469; gene.
DR   neXtProt; NX_Q02083; -.
DR   OpenTargets; ENSG00000138744; -.
DR   PharmGKB; PA162396672; -.
DR   eggNOG; ENOG410IJHJ; Eukaryota.
DR   eggNOG; ENOG4111HJY; LUCA.
DR   GeneTree; ENSGT00530000063548; -.
DR   HOGENOM; HOG000007253; -.
DR   HOVERGEN; HBG050586; -.
DR   InParanoid; Q02083; -.
DR   KO; K13720; -.
DR   OMA; RFLPQPF; -.
DR   OrthoDB; EOG091G0E3H; -.
DR   PhylomeDB; Q02083; -.
DR   TreeFam; TF313219; -.
DR   BRENDA; 3.5.1.4; 2681.
DR   Reactome; R-HSA-112310; Neurotransmitter Release Cycle.
DR   ChiTaRS; NAAA; human.
DR   GeneWiki; ASAHL; -.
DR   GenomeRNAi; 27163; -.
DR   PRO; PR:Q02083; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000138744; -.
DR   CleanEx; HS_NAAA; -.
DR   ExpressionAtlas; Q02083; baseline and differential.
DR   Genevisible; Q02083; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0016810; F:hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds; IDA:MGI.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:InterPro.
DR   GO; GO:0007269; P:neurotransmitter secretion; TAS:Reactome.
DR   InterPro; IPR016699; Acid_ceramidase-like.
DR   InterPro; IPR029130; Acid_ceramidase_N.
DR   InterPro; IPR029132; CBAH/NAAA_C.
DR   Pfam; PF02275; CBAH; 1.
DR   Pfam; PF15508; NAAA-beta; 1.
DR   PIRSF; PIRSF017632; Acid_ceramidase-like; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Autocatalytic cleavage; Complete proteome;
KW   Direct protein sequencing; Glycoprotein; Hydrolase; Lysosome;
KW   Polymorphism; Reference proteome; Signal; Zymogen.
FT   SIGNAL        1     28       {ECO:0000269|PubMed:22040171}.
FT   CHAIN        29    359       N-acylethanolamine-hydrolyzing acid
FT                                amidase.
FT                                /FTId=PRO_0000002318.
FT   CHAIN        29    125       N-acylethanolamine-hydrolyzing acid
FT                                amidase subunit alpha.
FT                                /FTId=PRO_0000419650.
FT   CHAIN       126    349       N-acylethanolamine-hydrolyzing acid
FT                                amidase subunit beta.
FT                                /FTId=PRO_0000419651.
FT   ACT_SITE    126    126       Nucleophile.
FT                                {ECO:0000305|PubMed:22040171}.
FT   CARBOHYD     37     37       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22040171}.
FT   CARBOHYD    107    107       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22040171}.
FT   CARBOHYD    309    309       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22040171}.
FT   CARBOHYD    333    333       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22040171}.
FT   VAR_SEQ     198    199       KG -> PE (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000328.
FT   VAR_SEQ     200    359       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000329.
FT   VAR_SEQ     324    359       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1446826}.
FT                                /FTId=VSP_000330.
FT   VARIANT     107    107       N -> K (in dbSNP:rs34751328).
FT                                /FTId=VAR_048336.
FT   VARIANT     151    151       V -> I (in dbSNP:rs4859571).
FT                                /FTId=VAR_028428.
FT   VARIANT     334    334       F -> L (in dbSNP:rs6823734).
FT                                /FTId=VAR_048337.
FT   CONFLICT    147    147       P -> A (in Ref. 4; AAA60119).
FT                                {ECO:0000305}.
FT   CONFLICT    240    240       T -> S (in Ref. 4; AAA60119).
FT                                {ECO:0000305}.
FT   CONFLICT    250    250       V -> L (in Ref. 4; AAA60119).
FT                                {ECO:0000305}.
SQ   SEQUENCE   359 AA;  40066 MW;  A8E214DB383B872A CRC64;
     MRTADREARP GLPSLLLLLL AGAGLSAASP PAAPRFNVSL DSVPELRWLP VLRHYDLDLV
     RAAMAQVIGD RVPKWVHVLI GKVVLELERF LPQPFTGEIR GMCDFMNLSL ADCLLVNLAY
     ESSVFCTSIV AQDSRGHIYH GRNLDYPFGN VLRKLTVDVQ FLKNGQIAFT GTTFIGYVGL
     WTGQSPHKFT VSGDERDKGW WWENAIAALF RRHIPVSWLI RATLSESENF EAAVGKLAKT
     PLIADVYYIV GGTSPREGVV ITRNRDGPAD IWPLDPLNGA WFRVETNYDH WKPAPKEDDR
     RTSAIKALNA TGQANLSLEA LFQILSVVPV YNNFTIYTTV MSAGSPDKYM TRIRNPSRK
//
